Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 5/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4018867 | 1.00 | DNM1 (0.48) | DNM1OPRM1FAAHEPHX2CNR1 | |
| SCHEMBL690816 | 1.00 | DNM1 (0.48) | DNM1OPRM1FAAHEPHX2CNR1 | |
| SCHEMBL9136425 | 1.00 | DNM1 (0.48) | DNM1OPRM1FAAHEPHX2CNR1 | |
| SCHEMBL10350856 | 1.00 | DNM1 (0.48) | DNM1OPRM1FAAHEPHX2CNR1 | |
| SCHEMBL17253503 | 1.00 | DNM1 (0.48) | DNM1OPRM1FAAHEPHX2CNR1 | |
| SCHEMBL4022359 | 1.00 | DNM1 (0.48) | DNM1OPRM1FAAHEPHX2CNR1 | |
| SCHEMBL3039218 | 1.00 | DNM1 (0.48) | DNM1OPRM1FAAHEPHX2CNR1 | |
| SCHEMBL7082641 | 1.00 | DNM1 (0.48) | DNM1OPRM1FAAHEPHX2CNR1 | |
| SCHEMBL11673316 | 1.00 | DNM1 (0.48) | DNM1OPRM1FAAHEPHX2CNR1 | |
| SCHEMBL11631045 | 1.00 | DNM1 (0.48) | DNM1OPRM1FAAHEPHX2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10335420-B2 | Nanoparticle-based tumor-targeted drug delivery | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-07-02 | — | — | US | disclosed |
| US-20170224838-A1 | NANOPARTICLE-BASED TUMOR-TARGETED DRUG DELIVERY | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170224838-A1 | NANOPARTICLE-BASED TUMOR-TARGETED DRUG DELIVERY | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224838-A1 | NANOPARTICLE-BASED TUMOR-TARGETED DRUG DELIVERY | LGMN, LAMP1, LNPEP | DNM1 1534/4885OPRM1 2410/4885FAAH 1664/4885 |
| US-10335420-B2 | Nanoparticle-based tumor-targeted drug delivery | LGMN, LAMP1, LNPEP | DNM1 1534/4885OPRM1 2410/4885FAAH 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.